Related Experiment Video

Updated: Jun 10, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs]

Yuli Wang1, Hongyu Liu, Jun Chen

  • 1Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenviroment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|August 4, 2010
PubMed

Insights

Epidermal growth factor receptor (EGFR) status, including mutations and amplification, predicts response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer. KRAS mutations indicate resistance to these targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
  • EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib are used for non-small cell lung cancer (NSCLC).
  • Individual responses to EGFR-TKIs vary significantly.

Purpose of the Study:

  • To investigate the role of EGFR status in predicting patient response to EGFR-TKIs.
  • To identify genetic markers associated with sensitivity or resistance to EGFR-TKI therapy in NSCLC.

Main Methods:

  • Analysis of multi-center clinical study data.
  • Evaluation of EGFR gene status, including mutations and amplification.
  • Assessment of KRAS mutation status.

Main Results:

  • EGFR mutations and amplification are critical factors predicting a good response to EGFR-TKIs.
  • KRAS mutations are associated with resistance to EGFR-TKIs.
  • EGFR status significantly influences treatment outcomes in NSCLC patients receiving TKIs.

Conclusions:

  • EGFR mutational and amplification status are crucial biomarkers for guiding EGFR-TKI therapy in NSCLC.
  • KRAS mutations serve as an indicator of resistance, necessitating alternative treatment strategies.
  • Personalized treatment approaches based on molecular profiling improve therapeutic efficacy in NSCLC.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...